Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder
NCT ID: NCT00385437
Last Updated: 2006-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
16 participants
INTERVENTIONAL
2003-04-30
2004-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
I) Using overnight sleep recordings, evaluate the short- and long-term sleep-promoting effects of the antidepressant mirtazapine (Remeron) in patients who have been prescribed this medication for major depressive disorder and sleep disruption.
II) Investigate the psychomotor performance of depressed patients using driving simulation testing before and during treatment with mitrazapine.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rationale:
The co-existence of depression and sleep difficulties are very common. Mirtazapine is marketed as a single modality of treatment for both depression and impaired sleep. As a sleep clinic in a psychiatry department, a single modality of treatment for depressive and sleep disorders is preferred by patients and can help improve compliance to treatment. However, there are only 7 published studies investigating the effects of mirtazapine and sleep and these have significant limitations. None of these studies have objectively examined mirtazapine's short- and long-term on sleep architecture and daytime function (daytime sleepiness, alertness, driving performance) in depressed patients. This study will address these issues.
Hypothesis:
I) Mirtazapine will produce both immediate and long- improvement effects on sleep in patients with major depressive disorders. There may be impairments in alertness for the first two days after starting treatment but daytime alertness will recover after one week.
II) Patients treated with mitrazapine will show a rapid, initial improvement in driving performance with recovery of sleep and slower, further improvement as treatment of their depression translates into better sleep quality as well as improvements in attention, alertness and concentration.
Study Design:
This pilot proposal is a two-part longitudinal, open-label clinical study with consecutive enrollment of subjects.
This research study will take place in conjunction with normal clinical practice. Patients with depression and sleep disorders are commonly seen in our sleep clinic and mirtazapine is one of several antidepressants that is prescribed by our clinicians. In this study, we will follow a group of patients who have been prescribed mirtazapine by one of our clinic physicians and who meet the inclusion and exclusion listed below. There will be an additional number of sleep studies (10 total versus the usual 2 or 3) performed; the usual daytime testing will be conducted as part of the standard of care (Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT)); we will administer additional questionnaires to assess subjective sleepiness, alertness and fatigue; and, driving simulator testing will be conducted in accordance with our normal standard of care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Driving Simulator Testing
Mirtazapine Treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score of Hamilton Rating Scale for Depression (HDRS-17) \> 17
* Patient to be prescribed mirtazapine (Remeron) as determined by physician
* Subject has no known clinically significant abnormal vital signs or other clinical findings at screening.
* Patients should have a driving license for more than 3 years and drive over 15,000 km year.
* Females of childbearing potential must willingly use effective birth control.
Exclusion Criteria
* A history or present condition of: Bipolar Disorder or Depressive Disorder not Otherwise Specified,Schizophrenia or other psychotic disorders (according to DSM-IV), Schizotypal or Borderline personality disorder, Organic mental disorders
* A present condition of: Anxiety Disorders (according to DSM-IV), Eating Disorders, Postpartum Depression
* Epilepsy or a history of seizure disorder or ever received treatment with anticonvulsant medication for epilepsy or seizures
* PSG recording of an extremely abnormal sleep EEG (other than that which would be expected with depression)
* Alcohol or substance abuse (according to DSM-IV) during the last 6months prior to baseline.
* Any physical disease, which may explain the symptoms of depression.
* Any chronic physical disease, which is not stabilized.
25 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon
INDUSTRY
University Health Network, Toronto
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Colin M. Shapiro, MBBCh, PhD
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Sharon A. Chung, PhD
Role: STUDY_DIRECTOR
University Health Network, Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bulmash EL, Moller HJ, Kayumov L, Shen J, Wang X, Shapiro CM. Psychomotor disturbance in depression: assessment using a driving simulator paradigm. J Affect Disord. 2006 Jul;93(1-3):213-8. doi: 10.1016/j.jad.2006.01.015. Epub 2006 Mar 7.
Shen J, Chung SA, Kayumov L, Moller H, Hossain N, Wang X, Deb P, Sun F, Huang X, Novak M, Appleton D, Shapiro CM. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006 Jan;51(1):27-34. doi: 10.1177/070674370605100106.
Shen J, Moller HJ, Wang X, Chung SA, Shapiro GK, Li X, Shapiro CM. Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients. J Clin Psychiatry. 2009 Mar;70(3):370-7. doi: 10.4088/jcp.08m04234. Epub 2009 Jan 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB-03-0255-A
Identifier Type: -
Identifier Source: org_study_id